Thirty patients with previously treated metastatic breast cancer were entered in a phase II study with oral lonidamine. Twenty-eight patients are evaluable for toxicity and 25 for response. A partial remission was obtained in four patients (16\%) and disease stability in 11 (44\%): 10 patients progressed (40\%). Toxicity was acceptable, consisting mainly of myalgias (39\% of patients) and asthenia (21.4\%). No myelotoxicity was observed. The drug is active in previously treated metastatic breast cancer and, because of its peculiar pattern of action and toxicity, deserves to be evaluated in combination with cytotoxic chemotherapy.
Phase II study of lonidamine in metastatic breast cancer / P., Pronzato; D., Amoroso; G., Bertelli; Conte, Pierfranco; M. P., Cusimano; G. B., Ciottoli; M., Gulisano; R., Lionetto; R., Rosso. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - STAMPA. - 59:(1989), pp. 251-253.
Phase II study of lonidamine in metastatic breast cancer.
CONTE, Pierfranco;
1989
Abstract
Thirty patients with previously treated metastatic breast cancer were entered in a phase II study with oral lonidamine. Twenty-eight patients are evaluable for toxicity and 25 for response. A partial remission was obtained in four patients (16\%) and disease stability in 11 (44\%): 10 patients progressed (40\%). Toxicity was acceptable, consisting mainly of myalgias (39\% of patients) and asthenia (21.4\%). No myelotoxicity was observed. The drug is active in previously treated metastatic breast cancer and, because of its peculiar pattern of action and toxicity, deserves to be evaluated in combination with cytotoxic chemotherapy.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
